Omics and therapy - A basis for precision medicine

Joseph P. Garay, Joe Gray

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

A founding premise of the human genome project was that knowledge of the spectrum of abnormalities that comprise cancers and other human diseases would lead to improved disease management by identifying molecular abnormalities that could guide disease detection and diagnosis, suggest new therapeutic strategies and be developed as markers to predict response to therapy. This project led to elucidation of a reference normal human genome sequence and normal polymorphisms therein against which sequences from diseased tissues can be compared to enable identification of causal abnormalities. It also stimulated development of an array of computational tools for genomic analysis and catalyzed public and private sector development of revolutionary tools for genome analysis that transformed analysis of whole genomes from an enterprise that required international teams and hundreds of millions of dollars to a process that can be carried out in core facilities for only a few thousand dollars per sample. Indeed, the $1000 genome is nearly upon us. Applications of these technologies to human cancers in international cancer genome projects are now revealing the spectra of abnormalities that comprise thousands of individual cancers. Analyses of these data are leading to the promised improvements in disease management. We review several aspects of cancer genomics with emphasis on aspects that are relevant to improving cancer therapy.

Original languageEnglish (US)
Pages (from-to)128-139
Number of pages12
JournalMolecular Oncology
Volume6
Issue number2
DOIs
StatePublished - Apr 2012

Fingerprint

Precision Medicine
Genome
Neoplasms
Disease Management
Therapeutics
Human Genome Project
Private Sector
Public Sector
Human Genome
Genomics
Technology

Keywords

  • Genomics
  • Personalized medicine
  • Targeted therapy

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Medicine

Cite this

Omics and therapy - A basis for precision medicine. / Garay, Joseph P.; Gray, Joe.

In: Molecular Oncology, Vol. 6, No. 2, 04.2012, p. 128-139.

Research output: Contribution to journalArticle

Garay, Joseph P. ; Gray, Joe. / Omics and therapy - A basis for precision medicine. In: Molecular Oncology. 2012 ; Vol. 6, No. 2. pp. 128-139.
@article{4ce6b4a6d66243dd9e96120ff37c262a,
title = "Omics and therapy - A basis for precision medicine",
abstract = "A founding premise of the human genome project was that knowledge of the spectrum of abnormalities that comprise cancers and other human diseases would lead to improved disease management by identifying molecular abnormalities that could guide disease detection and diagnosis, suggest new therapeutic strategies and be developed as markers to predict response to therapy. This project led to elucidation of a reference normal human genome sequence and normal polymorphisms therein against which sequences from diseased tissues can be compared to enable identification of causal abnormalities. It also stimulated development of an array of computational tools for genomic analysis and catalyzed public and private sector development of revolutionary tools for genome analysis that transformed analysis of whole genomes from an enterprise that required international teams and hundreds of millions of dollars to a process that can be carried out in core facilities for only a few thousand dollars per sample. Indeed, the $1000 genome is nearly upon us. Applications of these technologies to human cancers in international cancer genome projects are now revealing the spectra of abnormalities that comprise thousands of individual cancers. Analyses of these data are leading to the promised improvements in disease management. We review several aspects of cancer genomics with emphasis on aspects that are relevant to improving cancer therapy.",
keywords = "Genomics, Personalized medicine, Targeted therapy",
author = "Garay, {Joseph P.} and Joe Gray",
year = "2012",
month = "4",
doi = "10.1016/j.molonc.2012.02.009",
language = "English (US)",
volume = "6",
pages = "128--139",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Omics and therapy - A basis for precision medicine

AU - Garay, Joseph P.

AU - Gray, Joe

PY - 2012/4

Y1 - 2012/4

N2 - A founding premise of the human genome project was that knowledge of the spectrum of abnormalities that comprise cancers and other human diseases would lead to improved disease management by identifying molecular abnormalities that could guide disease detection and diagnosis, suggest new therapeutic strategies and be developed as markers to predict response to therapy. This project led to elucidation of a reference normal human genome sequence and normal polymorphisms therein against which sequences from diseased tissues can be compared to enable identification of causal abnormalities. It also stimulated development of an array of computational tools for genomic analysis and catalyzed public and private sector development of revolutionary tools for genome analysis that transformed analysis of whole genomes from an enterprise that required international teams and hundreds of millions of dollars to a process that can be carried out in core facilities for only a few thousand dollars per sample. Indeed, the $1000 genome is nearly upon us. Applications of these technologies to human cancers in international cancer genome projects are now revealing the spectra of abnormalities that comprise thousands of individual cancers. Analyses of these data are leading to the promised improvements in disease management. We review several aspects of cancer genomics with emphasis on aspects that are relevant to improving cancer therapy.

AB - A founding premise of the human genome project was that knowledge of the spectrum of abnormalities that comprise cancers and other human diseases would lead to improved disease management by identifying molecular abnormalities that could guide disease detection and diagnosis, suggest new therapeutic strategies and be developed as markers to predict response to therapy. This project led to elucidation of a reference normal human genome sequence and normal polymorphisms therein against which sequences from diseased tissues can be compared to enable identification of causal abnormalities. It also stimulated development of an array of computational tools for genomic analysis and catalyzed public and private sector development of revolutionary tools for genome analysis that transformed analysis of whole genomes from an enterprise that required international teams and hundreds of millions of dollars to a process that can be carried out in core facilities for only a few thousand dollars per sample. Indeed, the $1000 genome is nearly upon us. Applications of these technologies to human cancers in international cancer genome projects are now revealing the spectra of abnormalities that comprise thousands of individual cancers. Analyses of these data are leading to the promised improvements in disease management. We review several aspects of cancer genomics with emphasis on aspects that are relevant to improving cancer therapy.

KW - Genomics

KW - Personalized medicine

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84860495296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860495296&partnerID=8YFLogxK

U2 - 10.1016/j.molonc.2012.02.009

DO - 10.1016/j.molonc.2012.02.009

M3 - Article

C2 - 22445068

AN - SCOPUS:84860495296

VL - 6

SP - 128

EP - 139

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 2

ER -